» Articles » PMID: 35331175

Serum Untargeted Lipidomics by UHPLC-ESI-HRMS Aids the Biomarker Discovery of Colorectal Adenoma

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 Mar 25
PMID 35331175
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colorectal adenoma (CA) is an important precancerous lesion and early screening target of colorectal cancer (CRC). Lipids with numerous physiological functions are proved to be involved in the development of CRC. However, there is no lipidomic study with large-scale serum samples on diagnostic biomarkers for CA.

Methods: The serum lipidomics of CA patients (n = 50) and normal control (NR) (n = 50) was performed by ultra high performance liquid chromatography-high resolution mass spectrometry with electrospray ionization (UHPLC-ESI-HRMS). Univariate and multivariate statistical analyses were utilized to screen the differential lipids between groups, and combining the constituent ratio analysis and diagnostic efficiency evaluation by receiver operating characteristic (ROC) curve disclosed the potential mechanism and biomarkers for CA.

Results: There were obvious differences in serum lipid profiles between CA and NR groups. Totally, 79 differential lipids were selected by criterion of P < 0.05 and fold change > 1.5 or < 0.67. Triacylglycerols (TAGs) and phosphatidylcholines (PCs) were the major differential lipids with ratio > 60%, indicating these two lipid metabolic pathways showed evident disequilibrium, which could contribute to CA formation. Of them, 12 differential lipids had good diagnostic ability as candidate biomarkers for CA (AUC ≥ 0.900) by ROC analysis.

Conclusions: To our knowledge, this is the first attempt to profile serum lipidomics and explore lipid biomarkers of CA to help early screening of CRC. 12 differential lipids are obtained to act as potential diagnostic markers of CA. PCs and fatty acids were the main dysregulated biomarkers for CA in serum.

Citing Articles

Rapid Characterization of Phospholipids from Biological Matrix Enabled by Indium Tin Oxide (ITO) Coated Slide Assisted Enrichment MALDI Mass Spectrometry.

Huang P, Zhang H, Liu Y, Li L Anal Sens. 2024; 4(3).

PMID: 39309316 PMC: 11415247. DOI: 10.1002/anse.202300097.


The Utility of Lipidomic Analysis in Colorectal Cancer Diagnosis and Prognosis-A Systematic Review of Recent Literature.

Klekowski J, Chabowski M, Krzystek-Korpacka M, Fleszar M Int J Mol Sci. 2024; 25(14.

PMID: 39062964 PMC: 11277303. DOI: 10.3390/ijms25147722.


UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer.

Wang X, Guan X, Tong Y, Liang Y, Huang Z, Wen M BMC Cancer. 2024; 24(1):644.

PMID: 38802800 PMC: 11129395. DOI: 10.1186/s12885-024-12321-7.


Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022.

Gehin C, Fowler S, Trivedi D Anal Sci Adv. 2024; 4(3-4):104-131.

PMID: 38715925 PMC: 10989624. DOI: 10.1002/ansa.202300009.


HCMMD: systematic evaluation of metabolites in body fluids as liquid biopsy biomarker for human cancers.

Dong X, Qu Y, Sheng T, Fan Y, Chen S, Yuan Q Aging (Albany NY). 2024; 16(8):7487-7504.

PMID: 38683118 PMC: 11087094. DOI: 10.18632/aging.205779.


References
1.
Farshidfar F, Weljie A, Kopciuk K, Hilsden R, McGregor S, Buie W . A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics. Br J Cancer. 2016; 115(7):848-57. PMC: 5046202. DOI: 10.1038/bjc.2016.243. View

2.
Liu T, Peng F, Yu J, Tan Z, Rao T, Chen Y . LC-MS-based lipid profile in colorectal cancer patients: TAGs are the main disturbed lipid markers of colorectal cancer progression. Anal Bioanal Chem. 2019; 411(20):5079-5088. DOI: 10.1007/s00216-019-01872-5. View

3.
Cheng C, Geng F, Cheng X, Guo D . Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018; 38(1):27. PMC: 5993136. DOI: 10.1186/s40880-018-0301-4. View

4.
Cotte A, Aires V, Fredon M, Limagne E, Derangere V, Thibaudin M . Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. Nat Commun. 2018; 9(1):322. PMC: 5778070. DOI: 10.1038/s41467-017-02732-5. View

5.
Kurabe N, Hayasaka T, Ogawa M, Masaki N, Ide Y, Waki M . Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer; possible involvement of LPCAT4. Cancer Sci. 2013; 104(10):1295-302. PMC: 7656554. DOI: 10.1111/cas.12221. View